1,225
Views
0
CrossRef citations to date
0
Altmetric
Meningococcal

4CMenB journey to the 10-year anniversary and beyond

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon show all
Article: 2357924 | Received 19 Oct 2023, Accepted 17 May 2024, Published online: 08 Jul 2024

References

  • Shen J, Begum N, Ruiz-Garcia Y, Martinon-Torres F, Bekkat-Berkani R, Meszaros K. Range of invasive meningococcal disease sequelae and health economic application - a systematic and clinical review. BMC Public Health. 2022;22(1):1078. doi:10.1186/s12889-022-13342-2.
  • Deghmane AE, Taha S, Taha MK. Global epidemiology and changing clinical presentations of invasive meningococcal disease: a narrative review. Infect Dis (Lond). 2022;54(1):1–21. doi:10.1080/23744235.2021.1971289.
  • Parikh S, Campbell H, Bettinger JA, Harrison LH, Marshall HS, Martinon-Torres F, Safadi MA, Shao Z, Zhu B, von Gottberg A. et al. The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination. J Infect. 2020;81:483–98. doi:10.1016/j.jinf.2020.05.079.
  • U.S. Food & Drug Administration. PENBRAYA. 2023 [accessed 2024 Mar 15]. https://www.fda.gov/vaccines-blood-biologics/vaccines/penbraya.
  • Bekkat-Berkani R, Fragapane E, Preiss S, Rappuoli R, Sohn WY, Soumahoro L, Vadivelu K. Public health perspective of a pentavalent meningococcal vaccine combining antigens of MenACWY-CRM and 4CMenB. J Infect. 2022;85(5):481–91. doi:10.1016/j.jinf.2022.09.001.
  • Haidara FC, Umesi A, Sow SO, Ochoge M, Diallo F, Imam A, Traore Y, Affleck L, Doumbia MF, Daffeh B. et al. Meningococcal ACWYX conjugate vaccine in 2-to-29-year-olds in Mali and Gambia. N Engl J Med. 2023;388(21):1942–55. doi:10.1056/NEJMoa2214924.
  • Feavers IM, Maiden MCJ. Recent progress in the prevention of serogroup B meningococcal disease. Clin Vaccine Immunol. 2017;24(5):e00566. doi:10.1128/cvi.00566-16.
  • Holst J, Oster P, Arnold R, Tatley MV, Næss LM, Aaberge IS, Galloway Y, McNicholas A, O’Hallahan J, Rosenqvist E. et al. Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future. Hum Vaccin Immunother. 2013;9(6):1241–53. doi:10.4161/hv.24129.
  • De Gregorio E, Rappuoli R. From empiricism to rational design: a personal perspective of the evolution of vaccine development. Nat Rev Immunol. 2014;14(7):505–14. doi:10.1038/nri3694.
  • GSK. Bexsero prescribing information (U.S.A). 2022 [accessed 2024 Mar 15]. https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Bexsero/pdf/BEXSERO.PDF.
  • European Medicines Agency. Annex 1. Summary of product characteristics (Bexsero). 2020 [accessed 2024 Mar 15]. https://www.ema.europa.eu/en/documents/product-information/bexsero-epar-product-information_en.pdf.
  • Perez JL, Absalon J, Beeslaar J, Balmer P, Jansen KU, Jones TR, Harris S, York LJ, Jiang Q, Radley D. et al. From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine. Expert Rev Vaccines. 2018;17(6):461–77. doi:10.1080/14760584.2018.1483726.
  • Serruto D, Bottomley MJ, Ram S, Giuliani MM, Rappuoli R. The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine. 2012;30(Suppl 2):B87–97. doi:10.1016/j.vaccine.2012.01.033.
  • Rappuoli R, Pizza M, Masignani V, Vadivelu K. Meningococcal B vaccine (4CMenB): the journey from research to real world experience. Expert Rev Vaccines. 2018;17(12):1111–21. doi:10.1080/14760584.2018.1547637.
  • Aye AMM, Bai X, Borrow R, Bory S, Carlos J, Caugant DA, Chiou CS, Dai VTT, Dinleyici EC, Ghimire P. et al. Meningococcal disease surveillance in the Asia-Pacific region (2020): the global meningococcal initiative. J Infect. 2020;81(5):698–711. doi:10.1016/j.jinf.2020.07.025.
  • Asturias EJ, Bai X, Bettinger JA, Borrow R, Castillo DN, Caugant DA, Chacon GC, Dinleyici EC, Aviles GE, Garcia L. et al. Meningococcal disease in North America: updates from the global meningococcal initiative. J Infect. 2022;85(6):611–22. doi:10.1016/j.jinf.2022.10.022.
  • Dogu AG, Oordt-Speets AM, van Kessel-de Bruijn F, Ceyhan M, Amiche A. Systematic review of invasive meningococcal disease epidemiology in the Eastern Mediterranean and North Africa region. BMC Infect Dis. 2021;21(1):1088. doi:10.1186/s12879-021-06781-6.
  • Borrow R, Carlone GM, Rosenstein N, Blake M, Feavers I, Martin D, Zollinger W, Robbins J, Aaberge I, Granoff DM. et al. Neisseria meningitidis group B correlates of protection and assay standardization. International meeting report Emory University, Atlanta, Georgia, United States, 16–17 March 2005. Vaccine. 2006;24(24):5093–107. doi:10.1016/j.vaccine.2006.03.091.
  • O’Ryan M, Stoddard J, Toneatto D, Wassil J, Dull PM. A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program. Drugs. 2014;74(1):15–30. doi:10.1007/s40265-013-0155-7.
  • Martinón-Torres F, Carmona Martinez A, Simkó R, Infante Marquez P, Arimany JL, Gimenez-Sanchez F, Couceiro Gianzo JA, Kovács É, Rojo P, Wang H. et al. Antibody persistence and booster responses 24–36 months after different 4CMenB vaccination schedules in infants and children: a randomised trial. J Infect. 2018;76(3):258–69. doi:10.1016/j.jinf.2017.12.005.
  • Martinón-Torres F, Safadi MAP, Martinez AC, Marquez PI, Torres JCT, Weckx LY, Moreira EDJ, Mensi I, Calabresi M, Toneatto D. Reduced schedules of 4CMenB vaccine in infants and catch-up series in children: immunogenicity and safety results from a randomised open-label phase 3b trial. Vaccine. 2017;35(28):3548–57. doi:10.1016/j.vaccine.2017.05.023.
  • Biolchi A, Tomei S, Santini L, Welsch JA, Toneatto D, Gaitatzis N, Bai X, Borrow R, Giuliani MM, Mori E. et al. Evaluation of strain coverage of the multicomponent meningococcal serogroup B vaccine (4CMenB) administered in infants according to different immunisation schedules. Hum Vaccin Immunother. 2019;15(3):725–31. doi:10.1080/21645515.2018.1537756.
  • Govern d’Andorra. Recomanacions sobre l’administració de la vacunació enfront del meningococ B (Bexsero). 2016 [accessed 2024 Mar 15]. https://www.salut.ad/images/stories/Salut/pdfs/temes_salut/Recomanacions_Vacuna_Bexero.pdf.
  • Chile Ministerio de Salud. National immunization program. 2024 [accessed 2024 Mar 15]. https://www.minsal.cl/programa-nacional-de-inmunizaciones/.
  • European Centre for Disease Prevention and Control. Czechia: recommended vaccinations. 2024 [accessed 2024 Mar 15]. https://vaccine-schedule.ecdc.europa.eu/Scheduler/ByCountry?SelectedCountryId=201&IncludeChildAgeGroup=true&IncludeChildAgeGroup=false&IncludeAdultAgeGroup=true&IncludeAdultAgeGroup=false.
  • MUDr Jaromír Vomáčka. Vaccination against infectious diseases in the Czech Republic. 2023 [accessed 2024 Mar 15]. http://www.mudrvomacka.cz/index.php?option=com_content&view=article&id=8&Itemid=152&lang=en.
  • Ministère de la Santé et de la Prévention. Le calendrier des vaccinations. 2023 [accessed 2024 Mar 15]. https://sante.gouv.fr/prevention-en-sante/preserver-sa-sante/vaccination/calendrier-vaccinal.
  • Health Service Executive (Ireland). Immunisation schedule 2023. 2023 [accessed 2024 Mar 15]. https://www.hse.ie/eng/health/immunisation/pubinfo/currentschedule.html.
  • Ministero della Salute (Italy). Piano Nazionale Prevenzione Vaccinale PNPV 2023–2025. 2023 [accessed 2024 Mar 15]. https://www.quotidianosanita.it/allegati/allegato1679488094.pdf.
  • Ministry of Health for the Republic of Lithuania. Recommendation for revised vaccination against meningococcal type B infection. 2018 [accessed 2024 Mar 15]. https://nvsc.lrv.lt/uploads/nvsc/documents/files/Rekomendacijos%20skiepijant%20nuo%20B%20tipo%20MI(2).pdf.
  • Ministry of Health for the Republic of Lithuania. m. Birželio 12 d. Įsakymo nr. V-757 “dėl lietuvos respublikos vaikų profilaktinių skiepijimų kalendoriaus patvirtinimo“pakeitimo. 2018 [accessed 2024 Mar 15]. https://e-seimas.lrs.lt/portal/legalAct/lt/TAD/f4a925d0f50f11e79a1bc86190c2f01a.
  • Ministry for Health (Malta). National immunisation schedule. 2023 [accessed 2024 Mar 15]. https://healthservices.gov.mt/en/phc/pchyhi/Pages/National-Immunisation-Schedule.aspx.
  • Health New Zealand – Te Whatu Ora. New Zealand immunisation schedule. 2023 [accessed 2024 Mar 15]. https://www.tewhatuora.govt.nz/for-the-health-sector/vaccine-information/new-zealand-immunisation-schedule/.
  • Gabinete do Secretário de Estado da Saúde (Portugal). Aprova o novo esquema vacinal do Programa Nacional de Vacinação (PNV), revo-gando, com exceção do seu n.º 6, o Despacho n.º 10441/2016, de 9 de agosto. 2019 [accessed 2024 Mar 15]. https://files.dre.pt/2s/2019/12/250000000/0003000031.pdf.
  • SIP-SPP Vaccine Commission (Portugal). Recommendations on vaccines outside the national vaccination program. 2020 [accessed 2024 Mar 15]. https://www.spp.pt/UserFiles/file/Seccao_Infecciologia/recomendacoes%20vacinas_sip_final_28set_2.pdf.
  • Istituto per la Sicurezza Sociale (San Marino). Recommended vaccinations. 2023 [accessed 2024 Mar 15]. https://www.iss.sm/on-line/home/vaccini-e-vaccinazioni/vaccinazioni-raccomandate.html.
  • Asociación Española de Pediatría. Vacuna meningococo B. 2023 [accessed 2024 Mar 15]. https://vacunasaep.org/familias/vacunas-una-a-una/vacuna-meningococo-b.
  • Consejo Interterritorial del Sistema Nacional de Salud. Calendario común de vacunación a lo largo de toda la vida. Calendario recomendado año 2024. 2024 [accessed 2024 Mar 15]. https://www.sanidad.gob.es/areas/promocionPrevencion/vacunaciones/calendario/docs/CalendarioVacunacion_Todalavida.pdf.
  • Ladhani SN, Campbell H, Parikh SR, Saliba V, Borrow R, Ramsay M. The introduction of the meningococcal B (MenB) vaccine (Bexsero®) into the national infant immunisation programme - New challenges for public health. J Infect. 2015;71(6):611–4. doi:10.1016/j.jinf.2015.09.035.
  • UK Health Security Agency. The routine immunisation schedule. 2023 [accessed 2024 Mar 15]. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1055877/UKHSA-12155-routine-complete-immunisation-schedule_Feb2022.pdf.
  • Epidemiologisches Bulletin. STIKO: Standardimpfung von Säuglingen gegen Meningokokken der Serogruppe B. 2024 [accessed 2024 Mar 15]. https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2024/Ausgaben/03_24.pdf?__blob=publicationFile.
  • Higher Council of Infectious Diseases. Méningite et infections invasives à méningocoques. 2023 [accessed 2024 Mar 15]. https://sante.public.lu/fr/espace-professionnel/recommandations/conseil-maladies-infectieuses/meningite.html.
  • Office fédéral de la santé publique OFSP. Plan de vaccination suisse. 2024 [accessed 2024 Mar 15]. https://www.bag.admin.ch/bag/fr/home/gesund-leben/gesundheitsfoerderung-und-praevention/impfungen-prophylaxe/schweizerischer-impfplan.html.
  • Haute Autorité de Santé. Stratégie de vaccination contre les infections invasives à méningocoques. Révision de la stratégie contre les sérogroupes ACWY et B. 2024 [accessed 2024 Mar 15]. https://www.has-sante.fr/upload/docs/application/pdf/2024-03/eco_sp_424_recovac_meningo.pdf#page=8.
  • Mbaeyi SA, Bozio CH, Duffy J, Rubin LG, Hariri S, Stephens DS, MacNeil JR. Meningococcal vaccination: recommendations of the advisory committee on immunization practices, United States, 2020. MMWR Recomm Rep. 2020;69(9):1–41. doi:10.15585/mmwr.rr6909a1.
  • Centers for Disease Control and Prevention. Meningococcal vaccine recommendations. 2023 [accessed 2024 Mar 15]. https://www.cdc.gov/vaccines/vpd/mening/hcp/recommendations.html.
  • Marshall HS, Lally N, Flood L, Phillips P. First statewide meningococcal B vaccine program in infants, children and adolescents: evidence for implementation in South Australia. Med J Aust. 2020;212(2):89–93. doi:10.5694/mja2.50481.
  • Government of South Australia. Meningococcal B immunisation program. 2023 [accessed 2024 Mar 15]. https://www.sahealth.sa.gov.au/wps/wcm/connect/public+content/sa+health+internet/conditions/immunisation/immunisation+programs/meningococcal+b+immunisation+program.
  • Queensland Government. Immunisation schedule Queensland. 2024 [accessed 2024 Mar 15]. https://www.health.qld.gov.au/clinical-practice/guidelines-procedures/diseases-infection/immunisation/schedule.
  • Provincial government of Prince Edward Island. Free meningitis vaccine available to post-secondary students living in residence. 2023 [accessed 2024 Mar 15]. https://www.princeedwardisland.ca/en/news/free-meningitis-vaccine-available-to-post-secondary-students-living-in-residence.
  • Provincial government of Nova Scotia. More Nova Scotians eligible for meningococcal B vaccine. 2023 [accessed 2024 Mar 15]. https://novascotia.ca/news/release/?id=20230525003.
  • Abitbol V, Sohn WY, Horn M, Safadi MAP. Safety and immunogenicity of co-administered meningococcal serogroup B (4CMenB) vaccine: A literature review. Hum Vaccin Immunother. 2023;19(2):2245705. doi:10.1080/21645515.2023.2245705.
  • Sohn WY, Tahrat H, Novy P, Bekkat-Berkani R. Real-world implementation of 4-component meningococcal serogroup B vaccine (4CMenB): implications for clinical practices. Expert Rev Vaccines. 2022;21(3):325–35. doi:10.1080/14760584.2022.2021881.
  • Immunisation Advisory Centre (New Zealand). MenB Bexsero quick facts. 2023 [accessed 2024 Mar 15]. https://www.immune.org.nz/factsheets/menb-bexsero.
  • České vakcinologické společnosti ČLS JEP (Czechia). Doporučení České vakcinologické společnosti ČLS JEP pro očkování proti invazivním meningokokovým onemocněním. 2023 [accessed 2024 Mar 15]. https://www.vakcinace.eu/storage/files/3/doporuceni_a_stanoviska/2023/doporuceniockovaniprotiimofinal_6_3_2023.pdf.
  • Taha MK, Bekkat-Berkani R, Abitbol V. Changing patterns of invasive meningococcal disease and future immunization strategies. Hum Vaccin Immunother. 2023;19(1):2186111. doi:10.1080/21645515.2023.2186111.
  • Region of Puglia. Calendario vaccinale per la vita della regione Puglia - ed. 2021. 2021 [accessed 2024 Mar 15]. https://www.sanita.puglia.it/documents/20182/285275922/DGR+1589_2021+Nuovo+calendario+vaccinale+ed.2021.pdf/186500a3-134e-4dae-9d5c-c6e139280bcd.
  • Region of Calabria. DCA 43/2015 Calendario vaccinale regionale. 2022 [accessed 2024 Mar 15]. https://www.regione.calabria.it/website/portaltemplates/view/view_provvedimenti.cfm?63132.
  • Region of Sicilia. Il calendario vaccinale della Regione Sicilia. 2017 [accessed 2024 Mar 15]. https://www.vaccinarsinsicilia.org/vaccinazioni-sicilia/calendario-vaccinale.
  • Provincial government of Prince Edward Island. Meningococcal group A, B, C, Y and W-135 vaccines. 2023 [accessed 2024 Mar 15]. https://www.princeedwardisland.ca/en/information/health-and-wellness/meningococcal-group-a-b-c-y-and-w-135-vaccines.
  • Findlow J, Bai X, Findlow H, Newton E, Kaczmarski E, Miller E, Borrow R. Safety and immunogenicity of a four-component meningococcal group B vaccine (4CMenB) and a quadrivalent meningococcal group ACWY conjugate vaccine administered concomitantly in healthy laboratory workers. Vaccine. 2015;33(29):3322–30. doi:10.1016/j.vaccine.2015.05.027.
  • Macias Parra M, Gentile A, Vazquez Narvaez JA, Capdevila A, Minguez A, Carrascal M, Willemsen A, Bhusal C, Toneatto D. Immunogenicity and safety of the 4CMenB and MenACWY-CRM meningococcal vaccines administered concomitantly in infants: a phase 3b, randomized controlled trial. Vaccine. 2018;36(50):7609–17. doi:10.1016/j.vaccine.2018.10.096.
  • Beran J, Dražan D, Enweonye I, Bhusal C, Toneatto D. Immunogenicity and safety of investigational MenABCWY vaccine and of 4CMenB and MenACWY vaccines administered concomitantly or alone: A phase 2 randomized study of adolescents and young adults. mSphere. 2021;6(6):e0055321. doi:10.1128/mSphere.00553-21.
  • Martinón-Torres F, Banzhoff A, Azzari C, De Wals P, Marlow R, Marshall H, Pizza M, Rappuoli R, Bekkat-Berkani R. Recent advances in meningococcal B disease prevention: real-world evidence from 4CMenB vaccination. J Infect. 2021;83(1):17–26. doi:10.1016/j.jinf.2021.04.031.
  • Isitt C, Cosgrove CA, Ramsay ME, Ladhani SN. Success of 4CMenB in preventing meningococcal disease: evidence from real-world experience. Arch Dis Child. 2020;105(8):784–90. doi:10.1136/archdischild-2019-318047.
  • Cinconze E, Rosillon D, Rappuoli R, Vadivelu K, Bekkat-Berkani R, Abbing-Karahagopian V. Challenges in synthesis of real-world vaccine effects on meningococcal serogroup B disease for 4CMenB vaccine post-licensure effectiveness studies: a systematic review. Vaccine. 2023;41(30):4347–58. doi:10.1016/j.vaccine.2023.05.025.
  • Ladhani SN, Andrews N, Parikh SR, Campbell H, White J, Edelstein M, Bai X, Lucidarme J, Borrow R, Ramsay ME. Vaccination of infants with meningococcal group B vaccine (4CMenB) in England. N Engl J Med. 2020;382(4):309–17. doi:10.1056/NEJMoa1901229.
  • Lucidarme J, Bai X, Lekshmi A, Clark SA, Willerton L, Ribeiro S, Campbell H, Serino L, De Paola R, Holland A. et al. Invasive serogroup B meningococci in England following three years of 4CMenB vaccination - first real-world data. J Infect. 2022;84(2):136–44. doi:10.1016/j.jinf.2021.11.015.
  • Mensah AA, Campbell H, Clark SA, Ribeiro S, Lucidarme J, Bai X, Borrow R, Ladhani SN. Outcomes of meningococcal serogroup B disease in children after implementation of routine infant 4CMenB vaccination in England: an active, prospective, national surveillance study. Lancet Child Adolesc Health. 2023;7(3):190–8. doi:10.1016/s2352-4642(22)00379-0.
  • Deceuninck G, Lefebvre B, Tsang R, Betala-Belinga JF, De Serres G, De Wals P. Impact of a mass vaccination campaign against Serogroup B meningococcal disease in the Saguenay-Lac-Saint-Jean region of Quebec four years after its launch. Vaccine. 2019;37(31):4243–5. doi:10.1016/j.vaccine.2019.06.021.
  • De Wals P, Deceuninck G, Lefebvre B, Tsang R, Law D, De Serres G, Gilca V, Gilca R, Boulianne N. Impact of an immunization campaign to control an increased incidence of serogroup B meningococcal disease in one region of Quebec, Canada. Clin Infect Dis. 2017;64(9):1263–7. doi:10.1093/cid/cix154.
  • Banzhoff A. Multicomponent meningococcal B vaccination (4CMenB) of adolescents and college students in the United States. Ther Adv Vaccines. 2017;5(1):3–14. doi:10.1177/2051013616681365.
  • Biswas HH, Han GS, Wendorf K, Winter K, Zipprich J, Perti T, Martinez L, Arellano A, Kyle JL, Zhang P. et al. Notes from the field: Outbreak of serogroup B meningococcal disease at a university - California, 2016. MMWR Morb Mortal Wkly Rep. 2016;65(20):520–1. doi:10.15585/mmwr.mm6520a3.
  • Azzari C, Moriondo M, Nieddu F, Guarnieri V, Lodi L, Canessa C, Indolfi G, Giovannini M, Napoletano G, Russo F. et al. Effectiveness and impact of the 4CMenB vaccine against group B meningococcal disease in two Italian regions using different vaccination schedules: A five-year retrospective observational study (2014-2018). Vaccines (Basel). 2020;8(3):469. doi:10.3390/vaccines8030469.
  • Lodi L, Barbati F, Amicizia D, Baldo V, Barbui AM, Bondi A, Costantino C, Da Dalt L, Ferrara L, Fortunato F. et al. Four-component recombinant protein-based vaccine effectiveness against serogroup B meningococcal disease in Italy. JAMA Netw Open. 2023;6(8):e2329678. doi:10.1001/jamanetworkopen.2023.29678.
  • Rodrigues FMP, Marlow R, Simões MJ, Danon L, Ladhani S, Finn A. Association of use of a meningococcus group B vaccine with group B invasive meningococcal disease among children in Portugal. JAMA. 2020;324(21):2187–94. doi:10.1001/jama.2020.20449.
  • Castilla J, García Cenoz M, Abad R, Sánchez-Cambronero L, Lorusso N, Izquierdo C, Cañellas Llabrés S, Roig J, Malvar A, González Carril F. et al. Effectiveness of a meningococcal group B vaccine (4CMenB) in children. N Engl J Med. 2023;388(5):427–38. doi:10.1056/NEJMoa2206433.
  • McMillan M, Wang B, Koehler AP, Sullivan TR, Marshall HS. Impact of meningococcal B vaccine on invasive meningococcal disease in adolescents. Clin Infect Dis. 2021;73(1):233–7. doi:10.1093/cid/ciaa1636.
  • Marshall HS, McMillan M, Koehler AP, Lawrence A, Sullivan TR, MacLennan JM, Maiden MCJ, Ladhani SN, Ramsay ME, Trotter C. et al. Meningococcal B vaccine and meningococcal carriage in adolescents in Australia. N Engl J Med. 2020;382(4):318–27. doi:10.1056/NEJMoa1900236.
  • Wang B, Giles L, Andraweera P, McMillan M, Almond S, Beazley R, Mitchell J, Lally N, Ahoure M, Denehy E. et al. Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study. Lancet Infect Dis. 2022;22(7):1011–20. doi:10.1016/s1473-3099(21)00754-4.
  • Wang B, Giles L, Andraweera P, McMillan M, Almond S, Beazley R, Mitchell J, Ahoure M, Denehy E, Flood L. et al. 4CMenB sustained vaccine effectiveness against invasive meningococcal B disease and gonorrhoea at three years post programme implementation. J Infect. 2023;87(2):95–102. doi:10.1016/j.jinf.2023.05.021.
  • Marshall GS, Abbing-Karahagopian V, Marshall HS, Cenci S, Conway JH, Occhipinti E, Bekkat-Berkani R, Banzhoff A, Sohn WY. A comprehensive review of clinical and real-world safety data for the four-component serogroup B meningococcal vaccine (4CMenB). Expert Rev Vaccines. 2023;22(1):530–44. doi:10.1080/14760584.2023.2222015.
  • Deghmane AE, Taha MK. Product review on the IMD serogroup B vaccine Bexsero®. Hum Vaccin Immunother. 2022;18(1):e2020043. doi:10.1080/21645515.2021.2020043.
  • Gossger N, Snape MD, Yu LM, Finn A, Bona G, Esposito S, Principi N, Diez-Domingo J, Sokal E, Becker B. et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA. 2012;307(6):573–82. doi:10.1001/jama.2012.85.
  • Prymula R, Esposito S, Zuccotti GV, Xie F, Toneatto D, Kohl I, Dull PM. A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I). Hum Vaccin Immunother. 2014;10(7):1993–2004. doi:10.4161/hv.28666.
  • Vesikari T, Esposito S, Prymula R, Ypma E, Kohl I, Toneatto D, Dull P, Kimura A. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet. 2013;381(9869):825–35. doi:10.1016/s0140-6736(12)61961-8.
  • Ladhani SN, Riordan A. The yin and yang of fever after meningococcal B vaccination. Arch Dis Child. 2017;102(10):881–2. doi:10.1136/archdischild-2017-313419.
  • De Serres G, Billard MN, Gariépy MC, Rouleau I, Toth E, Landry M, Boulianne N, Gagné H, Gilca V, Deceuninck G. et al. Short-term safety of 4CMenB vaccine during a mass meningococcal B vaccination campaign in Quebec, Canada. Vaccine. 2018;36(52):8039–46. doi:10.1016/j.vaccine.2018.10.095.
  • Dubus M, Ladhani S, Vasu V. Prophylactic paracetamol after meningococcal B vaccination reduces postvaccination fever and septic screens in hospitalized preterm infants. Pediatr Infect Dis J. 2020;39(1):78–80. doi:10.1097/inf.0000000000002507.
  • Bryan P, Seabroke S, Wong J, Donegan K, Webb E, Goldsmith C, Vipond C, Feavers I. Safety of multicomponent meningococcal group B vaccine (4CMenB) in routine infant immunisation in the UK: a prospective surveillance study. Lancet Child Adolesc Health. 2018;2(6):395–403. doi:10.1016/s2352-4642(18)30103-2.
  • Hall GC, Douglas I, Heath PT, Prabhakar P, Rosillon D, Khan J, Abbing-Karahagopian V. Post-licensure observational safety study after meningococcal B vaccine 4CMenB (Bexsero) vaccination within the routine UK immunisation program. Vaccine. 2021;39(24):3296–303. doi:10.1016/j.vaccine.2021.02.065.
  • Mentzer D, Oberle D, Keller-Stanislawski B. Adverse events following immunisation with a meningococcal serogroup B vaccine: report from post-marketing surveillance, Germany, 2013 to 2016. Euro Surveill. 2018;23(17):17–00468. doi:10.2807/1560-7917.es.2018.23.17.17-00468.
  • Agenzia Italiana del Farmaco. Rapporto vaccini 2017. 2018 [accessed 2024 Mar 15]. https://www.aifa.gov.it/sites/default/files/Rapp_Vaccini_2017_0.pdf.
  • Marshall HS, Koehler AP, Wang B, A’Houre M, Gold M, Quinn H, Crawford N, Pratt N, Sullivan TR, Macartney K. Safety of meningococcal B vaccine (4CMenB) in adolescents in Australia. Vaccine. 2020;38(37):5914–22. doi:10.1016/j.vaccine.2020.07.009.
  • Australian Government Therapeutic Goods Administration. Bexsero meningococcal B vaccine. Final update - monitoring finds no new or unexpected safety issues. 2016 [accessed 2024 Mar 15]. https://www.tga.gov.au/news/safety-alerts/bexsero-meningococcal-b-vaccine.
  • Dey A, Wang H, Quinn H, Pillsbury A, Hickie M, Deng L, Wood N, Beard F, Macartney K. Surveillance of adverse events following immunisation in Australia annual report, 2020. Commun Dis Intell (2018). 2022;46. doi:10.33321/cdi.2022.46.47.
  • Watson PS, Turner DP. Clinical experience with the meningococcal B vaccine, Bexsero®: prospects for reducing the burden of meningococcal serogroup B disease. Vaccine. 2016;34(7):875–80. doi:10.1016/j.vaccine.2015.11.057.
  • Thabuis A, Tararbit K, Taha MK, Dejour-Salamanca D, Ronin V, Parent du Chatelet I, Spaccaferri G. Community outbreak of serogroup B invasive meningococcal disease in Beaujolais, France, February to June 2016: from alert to targeted vaccination. Euro Surveill. 2018;23(28):1700590. doi:10.2807/1560-7917.es.2018.23.28.1700590.
  • De Serres G, Billard MN, Gariépy MC, Roy MC, Boucher FD, Gagné H, Belley S, Toth E, Landry M, Skowronski DM. Nephrotic syndrome following four-component meningococcal B vaccination: epidemiologic investigation of a surveillance signal. Vaccine. 2019;37(35):4996–5002. doi:10.1016/j.vaccine.2019.07.017.
  • Andrews N, Stowe J, Miller E. Nephrotic syndrome in infants and toddlers before and after introduction of the meningococcal B vaccine programme in England: an ecological study. Vaccine. 2020;38(31):4816–9. doi:10.1016/j.vaccine.2020.05.055.
  • Stowe J, Andrews NJ, Turner PJ, Miller E. The risk of Kawasaki disease after pneumococcal conjugate & meningococcal B vaccine in England: a self-controlled case-series analysis. Vaccine. 2020;38(32):4935–9. doi:10.1016/j.vaccine.2020.05.089.
  • Ruiz García Y, Sohn WY, Seib KL, Taha MK, Vázquez JA, de Lemos APS, Vadivelu K, Pizza M, Rappuoli R, Bekkat-Berkani R. Looking beyond meningococcal B with the 4CMenB vaccine: the Neisseria effect. NPJ Vaccines. 2021;6(1):130. doi:10.1038/s41541-021-00388-3.
  • Biolchi A, De Angelis G, Moschioni M, Tomei S, Brunelli B, Giuliani M, Bambini S, Borrow R, Claus H, Gorla MCO. et al. Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolates. Vaccine. 2020;38(47):7542–50. doi:10.1016/j.vaccine.2020.09.050.
  • Biolchi A, Tomei S, Brunelli B, Giuliani M, Bambini S, Borrow R, Claus H, Gorla MCO, Hong E, Lemos APS. et al. 4CMenB immunization induces serum bactericidal antibodies against non-serogroup B meningococcal strains in adolescents. Infect Dis Ther. 2021;10(1):307–16. doi:10.1007/s40121-020-00370-x.
  • Hong E, Giuliani MM, Deghmane AE, Comanducci M, Brunelli B, Dull P, Pizza M, Taha MK. Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa? Vaccine. 2013;31(7):1113–16. doi:10.1016/j.vaccine.2012.12.022.
  • Ladhani SN, Campbell H, Andrews N, Parikh SR, White J, Edelstein M, Clark SA, Lucidarme J, Borrow R, Ramsay ME. First real-world evidence of meningococcal group B vaccine, 4CMenB, protection against meningococcal group W disease: Prospective enhanced national surveillance, England. Clin Infect Dis. 2021;73(7):1661–8. doi:10.1093/cid/ciaa1244.
  • Semchenko EA, Day CJ, Seib KL. The Neisseria gonorrhoeae vaccine candidate NHBA elicits antibodies that are bactericidal, opsonophagocytic and that reduce gonococcal adherence to epithelial cells. Vaccines. 2020;8(2):219. doi:10.3390/vaccines8020219.
  • Semchenko EA, Tan A, Borrow R, Seib KL. The serogroup B meningococcal vaccine Bexsero elicits antibodies to Neisseria gonorrhoeae. Clin Infect Dis. 2019;69(7):1101–11. doi:10.1093/cid/ciy1061.
  • Petousis-Harris H, Paynter J, Morgan J, Saxton P, McArdle B, Goodyear-Smith F, Black S. Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study. Lancet. 2017;390(10102):1603–10. doi:10.1016/s0140-6736(17)31449-6.
  • Paynter J, Goodyear-Smith F, Morgan J, Saxton P, Black S, Petousis-Harris H. Effectiveness of a group B outer membrane vesicle meningococcal vaccine in preventing hospitalization from gonorrhea in New Zealand: a retrospective cohort study. Vaccines (Basel). 2019;7(1):5. doi:10.3390/vaccines7010005.
  • Tuddenham S, Hamill MM, Ghanem KG. Diagnosis and treatment of sexually transmitted infections: a review. JAMA. 2022;327(2):161–72. doi:10.1001/jama.2021.23487.
  • Frost I, Sati H, Garcia-Vello P, Hasso-Agopsowicz M, Lienhardt C, Gigante V, Beyer P. The role of bacterial vaccines in the fight against antimicrobial resistance: an analysis of the preclinical and clinical development pipeline. Lancet Microbe. 2023;4(2):e113–25. doi:10.1016/s2666-5247(22)00303-2.
  • ClinicalTrials.gov. Study to assess gonorrhoeae immune responses induced by a N. Meningitidis vaccine (4cmenB). 2021 [accessed 2024 Mar 15]. https://www.clinicaltrials.gov/study/NCT04094883?term=NCT04094883&rank=1.
  • ClinicalTrials.gov. Efficacy of immunization with 4C-MenB in preventing experimental urethral infection with Neisseria gonorrhoeae. 2023 [accessed 2024 Mar 15]. https://www.clinicaltrials.gov/study/NCT05294588?term=NCT05294588&rank=1.
  • Robison SG, Leman RF. Association of group B meningococcal vaccine receipt with reduced gonorrhea incidence among university students. JAMA Netw Open. 2023;6(8):e2331742. doi:10.1001/jamanetworkopen.2023.31742.
  • Bruxvoort KJ, Lewnard JA, Chen LH, Tseng HF, Chang J, Veltman J, Marrazzo J, Qian L. Prevention of Neisseria gonorrhoeae with meningococcal B vaccine: A matched cohort study in southern California. Clin Infect Dis. 2023;76(3):1341–9. doi:10.1093/cid/ciac436.
  • ClinicalTrials.gov. Mucosal immunity against Neisseria gonorrhoeae after 4CMenB vaccination. 2023 [accessed 2024 Mar 15]. https://www.clinicaltrials.gov/study/NCT04722003?term=NCT04722003&rank=1.
  • Abara WE, Bernstein KT, Lewis FMT, Schillinger JA, Feemster K, Pathela P, Hariri S, Islam A, Eberhart M, Cheng I. et al. Effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhoea: a retrospective observational study. Lancet Infect Dis. 2022;22(7):1021–9. doi:10.1016/s1473-3099(21)00812-4.
  • Longtin J, Dion R, Simard M, Betala Belinga J-F, Longtin Y, Lefebvre B, Labbé A-C, Deceuninck G, De Wals P. Possible impact of wide-scale vaccination against serogroup B Neisseria meningitidis on gonorrhea incidence rates in one region of Quebec, Canada. Open Forum Infect Dis. 2017;4(Suppl 1):S734–5. doi:10.1093/ofid/ofx180.002.
  • ClinicalTrials.gov. Safety and efficacy study of meningococcal group B vaccine rMenB+OMV NZ (Bexsero) to prevent gonococcal infection. 2024 [accessed 2024 Mar 15]. https://www.clinicaltrials.gov/study/NCT04350138?term=NCT04350138&rank=1.
  • Raccagni AR, Galli L, Spagnuolo V, Bruzzesi E, Muccini C, Bossolasco S, Ranzenigo M, Gianotti N, Lolatto R, Castagna A. et al. Meningococcus B vaccination effectiveness against Neisseria gonorrhoeae infection in people living with HIV: A case-control study. Sex Transm Dis. 2023;50(5):247–51. doi:10.1097/olq.0000000000001771.
  • ClinicalTrials.gov. Gonococcal vaccine study in key populations in Kenya (BexKPK). 2022 [accessed 2024 Mar 15]. https://www.clinicaltrials.gov/study/NCT04297436?term=NCT04297436&rank=1.
  • ClinicalTrials.gov. Efficacy trial on meningococcal B vaccine for preventing gonorrhea infections. 2023 [accessed 2024 Mar 15]. https://www.clinicaltrials.gov/study/NCT05766904?term=NCT05766904&rank=1.
  • ClinicalTrials.gov. Immunisation for adolescents against serious communicable diseases (B Part of it NT). 2023 [accessed 2024 Mar 15]. https://www.clinicaltrials.gov/study/NCT04398849?term=NCT04398849&rank=1.
  • ClinicalTrials.gov. Efficacy study of 4CMenB (Bexsero®) to prevent gonorrhoea infection in gay and bisexual men (GoGovax). 2023 [accessed 2024 Mar 15]. https://www.clinicaltrials.gov/study/NCT04415424?term=NCT04415424&rank=1.
  • Australian New Zealand Clinical Trials Registry. MenGO: Does the licensed meningococcal vaccine Bexsero® provide cross- protection against gonorrhoea in gay and bisexual men? 2023 [accessed 2024 Mar 15]. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12619001478101.
  • Molina J-M, Berçot B, Assoumou L, Algarte-Genin M, Rubenstein E, Pialoux G, Katlama C, Surgers L, Bebear C, Dupin N. et al. Final results of ANRS 174 DOXYVAC: A randomized trial to prevent STI in MSM on PrEP. Conference on Retroviruses and Opportunistic Infections Abstract book (Abstract 124); 2024 Mar 3-6; Denver, Colorado, USA https://www.croiconference.org/abstract/final-results-of-anrs-174-doxyvac-a-randomized-trial-to-prevent-sti-in-msm-on-prep/.
  • Abara WE, Bernstein KT, Lewis FMT, Pathela P, Islam A, Eberhart M, Cheng I, Ternier A, Sanderson Slutsker J, Madera R. et al. Healthy vaccinee bias and MenB-FHbp vaccine effectiveness against gonorrhea. Sex Transm Dis. 2023;50(6):e8–10. doi:10.1097/olq.0000000000001793.
  • Molina J-M, Berçot B, Assoumou L, Algarte-Genin M, Rubenstein E, Pialoux G, Katlama C, Surgers L, Bebear C, Dupin N. et al. Final results of ANRS 174 DOXYVAC: A randomized trial to prevent STIs in MSM on PrEP. Slides presented at Conference on Retroviruses and Opportunistic Infections; 2024 Mar 3–6 [accessed 2024 Mar 15]; Denver, Colorado, USA. https://www.natap.org/2024/CROI/croi_33.htm.
  • Looker KJ, Booton R, Begum N, Beck E, Shen J, Turner KME, Christensen H. The potential public health impact of adolescent 4CMenB vaccination on Neisseria gonorrhoeae infection in England: a modelling study. BMC Public Health. 2023;23(1):1. doi:10.1186/s12889-022-14670-z.
  • Carey KA, Newman LM, Spicknall IH. Estimating the population level impact of a gonococcal vaccine candidate: predictions from a simple mathematical model. Vaccine. 2022;40(50):7176–81. doi:10.1016/j.vaccine.2022.10.031.
  • U.S. Department of Health and Human Services. Reduce gonorrhea rates in male adolescents and young men — STI‑02. 2020 [accessed 2024 Mar 15]. https://health.gov/healthypeople/objectives-and-data/browse-objectives/sexually-transmitted-infections/reduce-gonorrhea-rates-male-adolescents-and-young-men-sti-02.
  • European Centre for Disease Prevention and Control. Invasive meningococcal disease. Annual epidemiological report for 2021. 2023 [accessed 2024 Mar 15]. https://www.ecdc.europa.eu/sites/default/files/documents/MEN%20AER%202021.pdf.
  • Centers for Disease Control and Prevention. Meningococcal disease Surveillance and Trends. 2024 [accessed 2024 Mar 15]. https://www.cdc.gov/meningococcal/php/surveillance/?CDC_AAref_Val=https://www.cdc.gov/meningococcal/surveillance/index.html.
  • Martinón-Torres F, Nolan T, Toneatto D, Banzhoff A. Persistence of the immune response after 4CMenB vaccination, and the response to an additional booster dose in infants, children, adolescents, and young adults. Hum Vaccin Immunother. 2019;15(12):2940–51. doi:10.1080/21645515.2019.1627159.
  • Watson PS, Novy P, Bekkat-Berkani R, Strubbe F, Banzhoff A. Optimizing the timing of 4CMenB vaccination in adolescents and young adults based on immune persistence and booster response data. Expert Rev Vaccines. 2019;18(4):343–52. doi:10.1080/14760584.2019.1580579.
  • Guedes S, Bertrand-Gerentes I, Evans K, Coste F, Oster P. Invasive meningococcal disease in older adults in North America and Europe: is this the time for action? A review of the literature. BMC Public Health. 2022;22(1):380. doi:10.1186/s12889-022-12795-9.
  • Acevedo R, Bai X, Borrow R, Caugant DA, Carlos J, Ceyhan M, Christensen H, Climent Y, De Wals P, Dinleyici EC. et al. The global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations. Expert Rev Vaccines. 2019;18(1):15–30. doi:10.1080/14760584.2019.1557520.
  • Burman C, Findlow J, Marshall HS, Safadi MAP. National and regional differences in meningococcal vaccine recommendations for individuals at an increased risk of meningococcal disease. Expert Rev Vaccines. 2023;22(1):839–48. doi:10.1080/14760584.2023.2245467.
  • Chang L, Lim BCW, Flaherty GT, Torresi J. Travel vaccination recommendations and infection risk in HIV-positive travellers. J Travel Med. 2019;26(6):taz034. doi:10.1093/jtm/taz034.
  • Bozio CH, Blain A, MacNeil J, Retchless A, Weil LM, Wang X, Jenkins LT, Rodriguez-Rivera LD, Jarashow C, Ngo V. et al. Meningococcal disease surveillance in men who have sex with men - United States, 2015-2016. MMWR Morb Mortal Wkly Rep. 2018;67(38):1060–3. doi:10.15585/mmwr.mm6738a4.
  • Folaranmi TA, Kretz CB, Kamiya H, MacNeil JR, Whaley MJ, Blain A, Antwi M, Dorsinville M, Pacilli M, Smith S. et al. Increased risk for meningococcal disease among men who have sex with men in the United States, 2012–2015. Clin Infect Dis. 2017;65(5):756–63. doi:10.1093/cid/cix438.
  • Simmons RD, Kirwan P, Beebeejaun K, Riordan A, Borrow R, Ramsay ME, Delpech V, Lattimore S, Ladhani S. Risk of invasive meningococcal disease in children and adults with HIV in England: a population-based cohort study. BMC Med. 2015;13(1):297. doi:10.1186/s12916-015-0538-6.
  • Marshall GS, Ghaswalla PK, Bengtson LGS, Buikema AR, Bancroft T, Koep E, Novy P, Hogea CS. Low meningococcal vaccination rates among patients with newly diagnosed complement component deficiencies in the United States. Clin Infect Dis. 2022;75(1):155–8. doi:10.1093/cid/ciab917.
  • Ghaswalla PK, Bengtson LGS, Marshall GS, Buikema AR, Bancroft T, Schladweiler KM, Koep E, Novy P, Hogea CS. Meningococcal vaccination in patients with newly diagnosed asplenia in the United States. Vaccine. 2021;39(2):272–81. doi:10.1016/j.vaccine.2020.11.068.
  • Ghaswalla PK, Marshall GS, Bengtson LGS, Buikema AR, Bancroft T, Koep E, Novy P, Hogea CS. Meningococcal vaccination rates among people with a new diagnosis of HIV infection in the US. JAMA Netw Open. 2022;5(4):e228573. doi:10.1001/jamanetworkopen.2022.8573.
  • de Oliveira Costa J, Gianacas C, Beard F, Gonzalez-Chica D, Chidwick K, Osman R, MacIntyre CR, Havard A. Cumulative annual coverage of meningococcal B vaccination in Australian general practice for three at-risk groups, 2014 to 2019. Hum Vaccin Immunother. 2021;17(10):3692–701. doi:10.1080/21645515.2021.1923349.
  • Orangzeb S, Watle SV, Caugant DA. Adherence to vaccination guidelines of patients with complete splenectomy in Norway, 2008-2020. Vaccine. 2023;41(31):4579–85. doi:10.1016/j.vaccine.2023.06.034.
  • Martinón-Torres F, Bernatowska E, Shcherbina A, Esposito S, Szenborn L, Marti MC, Hughes S, Faust SN, Gonzalez-Granado LI, Yu LM. et al. Meningococcal B vaccine immunogenicity in children with defects in complement and splenic function. Pediatrics. 2018;142(3):e20174250. doi:10.1542/peds.2017-4250.
  • van den Broek B, van Els C, Kuipers B, van Aerde K, Henriet SS, de Groot R, de Jonge MI, Langereis JD, van der Flier M. Multi-component meningococcal serogroup B (MenB)-4C vaccine induces effective opsonophagocytic killing in children with a complement deficiency. Clin Exp Immunol. 2019;198(3):381–9. doi:10.1111/cei.13368.
  • Robin C, Redjoul R, Terrade A, Deghmane AE, Cabanne L, Cordonnier C, Taha MK. Immunogenicity and safety of the meningococcal B recombinant (4CMenB) vaccine in allogeneic hematopoietic cell transplantation recipients. Clin Microbiol Infect. 2022;28(12):1609–14. doi:10.1016/j.cmi.2022.06.024.
  • Isitt C, Bartolf A, Andrews N, Athaide S, Pryce-Williams R, Townsend-Payne K, Borrow R, Ladhani S, Heath PT, Cosgrove CA. The propositive study: Immunogenicity and safety of a four-component recombinant protein-based vaccine against MenB and a quadrivalent conjugate MenACWY vaccine in people living with HIV. HIV Med. 2023;24(9):979–89. doi:10.1111/hiv.13495.
  • San Francisco Ramos A, Isitt C, Athaide S, Ladhani SN, Andrews NJ, Townsend-Payne K, Holland A, Louth J, Borrow R, Heath PT. et al. Propositive follow-up: Long-term immune responses to the 4CMenB and MenACWY vaccines in people living with HIV. HIV Med. 2024;25(3):370–80. doi:10.1111/hiv.13586.
  • Hernando Real S, Vega Castano S, Pajares Garcia R, Meije Y. Meningococcemia in vaccinated patient under treatment with eculizumab. Enferm Infecc Microbiol Clin. 2017;35(3):200–1. doi:10.1016/j.eimc.2016.02.015.
  • World Health Organization. Defeating meningitis by 2030: a global road map. 2021 [accessed 2024 Mar 15]. https://www.who.int/publications/i/item/9789240026407.
  • Taha MK, Martinon-Torres F, Köllges R, Bonanni P, Safadi MAP, Booy R, Smith V, Garcia S, Bekkat-Berkani R, Abitbol V. Equity in vaccination policies to overcome social deprivation as a risk factor for invasive meningococcal disease. Expert Rev Vaccines. 2022;21(5):659–74. doi:10.1080/14760584.2022.2052048.
  • Taha MK, Weil-Olivier C, Bouée S, Emery C, Nachbaur G, Pribil C, Loncle-Provot V. Risk factors for invasive meningococcal disease: a retrospective analysis of the French national public health insurance database. Hum Vaccin Immunother. 2021;17(6):1858–66. doi:10.1080/21645515.2020.1849518.
  • Gras-Le Guen C, Vignier N, Kochert F, Javouhey E, Launay E, Dufour V, Gaudelus J, Launay O, Stahl JP, Tattevin P. et al. Why should the meningococcal B vaccine be recommended, and therefore reimbursed, for infants in France? Infect Dis Now. 2021;51(5):407–9. doi:10.1016/j.idnow.2021.05.001.
  • Borrow R, Taha MK, Giuliani MM, Pizza M, Banzhoff A, Bekkat-Berkani R. Methods to evaluate serogroup B meningococcal vaccines: from predictions to real-world evidence. J Infect. 2020;81(6):862–72. doi:10.1016/j.jinf.2020.07.034.
  • Obergfell KP, Seifert HS. Mobile DNA in the pathogenic Neisseria. Microbiol Spectr. 2015;3(1):MDNA3–0015–2014. doi:10.1128/microbiolspec.MDNA3-0015-2014.
  • Rotman E, Seifert HS. The genetics of Neisseria species. Annu Rev Genet. 2014;48(1):405–31. doi:10.1146/annurev-genet-120213-092007.
  • Plikaytis BD, Stella M, Boccadifuoco G, DeTora LM, Agnusdei M, Santini L, Brunelli B, Orlandi L, Simmini I, Giuliani M. et al. Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines. Clin Vaccine Immunol. 2012;19(10):1609–17. doi:10.1128/cvi.00202-12.
  • Donnelly J, Medini D, Boccadifuoco G, Biolchi A, Ward J, Frasch C, Moxon ER, Stella M, Comanducci M, Bambini S. et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci USA. 2010;107(45):19490–5. doi:10.1073/pnas.1013758107.
  • Muzzi A, Brozzi A, Serino L, Bodini M, Abad R, Caugant D, Comanducci M, Lemos AP, Gorla MC, Křížová P. et al. Genetic Meningococcal Antigen Typing System (gMATS): a genotyping tool that predicts 4CMenB strain coverage worldwide. Vaccine. 2019;37(7):991–1000. doi:10.1016/j.vaccine.2018.12.061.
  • Medini D, Stella M, Wassil J. MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine. Vaccine. 2015;33(23):2629–36. doi:10.1016/j.vaccine.2015.04.015.
  • Tzanakaki G, Hong E, Kesanopoulos K, Xirogianni A, Bambini S, Orlandi L, Comanducci M, Muzzi A, Taha MK. Diversity of Greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccine. BMC Microbiol. 2014;14(1):111. doi:10.1186/1471-2180-14-111.
  • Vogel U, Taha MK, Vazquez JA, Findlow J, Claus H, Stefanelli P, Caugant DA, Kriz P, Abad R, Bambini S. et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis. 2013;13(5):416–25. doi:10.1016/s1473-3099(13)70006-9.
  • Waśko I, Hong E, De Paola R, Stella M, Moschioni M, Taha MK, Skoczyńska A. High predicted strain coverage by the multicomponent meningococcal serogroup B vaccine (4CMenB) in Poland. Vaccine. 2016;34(4):510–5. doi:10.1016/j.vaccine.2015.11.070.
  • Bodini M, Brozzi A, Giuliani M, Nohynek H, Vainio A, Kuusi M, De Paola R, Pizza M, Medini D, Toropainen M. et al. Genomic characterization of invasive meningococcal serogroup B isolates and estimation of 4CMenB vaccine coverage in Finland. mSphere. 2020;5(5):e00376–20. doi:10.1128/mSphere.00376-20.
  • Křížová P, Musílek M, Vacková Z, Kozáková J, Claus H, Vogel U, Medini D. Predicted strain coverage of a new protein-based meningococcal vaccine in the Czech Republic. Epidemiol Mikrobiol Imunol. 2014;63(2):103–6.
  • Tsang RSW, Law DKS, De Paola R, Giuliani M, Stella M, Zhou J, Deng S, Boccadifuoco G, Giuliani MM, Serino L. Culture-confirmed invasive meningococcal disease in Canada, 2010 to 2014: Characterization of serogroup B Neisseria meningitidis strains and their predicted coverage by the 4CMenB vaccine. mSphere. 2020;5(2):e00883–19. doi:10.1128/mSphere.00883-19.
  • Parikh SR, Newbold L, Slater S, Stella M, Moschioni M, Lucidarme J, De Paola R, Giuliani M, Serino L, Gray SJ. et al. Meningococcal serogroup B strain coverage of the multicomponent 4CMenB vaccine with corresponding regional distribution and clinical characteristics in England, Wales, and Northern Ireland, 2007-08 and 2014-15: a qualitative and quantitative assessment. Lancet Infect Dis. 2017;17(7):754–62. doi:10.1016/s1473-3099(17)30170-6.
  • Mulhall RM, Bennett D, Cunney R, Borrow R, Lucidarme J, Findlow J, Jolley KA, Bray J, Maiden MCJ, Moschioni M. et al. Potential coverage of the 4CMenB vaccine against invasive serogroup B Neisseria meningitidis isolated from 2009 to 2013 in the Republic of Ireland. mSphere. 2018;3(4):e00196–18. doi:10.1128/mSphere.00196-18.
  • Abad R, Medina V, Stella M, Boccadifuoco G, Comanducci M, Bambini S, Muzzi A, Vazquez JA. Predicted strain coverage of a new meningococcal multicomponent vaccine (4CMenB) in Spain: Analysis of the differences with other European countries. PLOS ONE. 2016;11(3):e0150721. doi:10.1371/journal.pone.0150721.
  • Simões MJ, Bettencourt C, De Paola R, Giuliani M, Pizza M, Moschioni M, Machado J. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Portugal. PLOS ONE. 2017;12(5):e0176177. doi:10.1371/journal.pone.0176177.
  • Hong E, Terrade A, Muzzi A, De Paola R, Boccadifuoco G, La Gaetana R, Deghmane AE, Pizza M, Serino L, Taha MK. Evolution of strain coverage by the multicomponent meningococcal serogroup B vaccine (4CMenB) in France. Hum Vaccin Immunother. 2021;17(12):5614–22. doi:10.1080/21645515.2021.2004055.
  • Tozer SJ, Smith HV, Whiley DM, Borrow R, Boccadifuoco G, Medini D, Serruto D, Giuliani MM, Stella M, De Paola R. et al. High coverage of diverse invasive meningococcal serogroup B strains by the 4-component vaccine 4CMenB in Australia, 2007-2011: Concordant predictions between MATS and genetic MATS. Hum Vaccin Immunother. 2021;17(9):3230–8. doi:10.1080/21645515.2021.1904758.
  • Freudenburg-de Graaf W, Knol MJ, van der Ende A. Predicted coverage by 4CMenB vaccine against invasive meningococcal disease cases in the Netherlands. Vaccine. 2020;38(49):7850–7. doi:10.1016/j.vaccine.2020.10.008.
  • Lodi L, Moriondo M, Nieddu F, Ricci S, Guiducci S, Lippi F, Canessa C, Calistri E, Citera F, Giovannini M. et al. Molecular typing of group B Neisseria meningitidis’ subcapsular antigens directly on biological samples demonstrates epidemiological congruence between culture-positive and -negative cases: A surveillance study of invasive disease over a 13-year period. J Infect. 2021;82(4):28–36. doi:10.1016/j.jinf.2020.12.034.
  • Frosi G, Biolchi A, Lo Sapio M, Rigat F, Gilchrist S, Lucidarme J, Findlow J, Borrow R, Pizza M, Giuliani MM. et al. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine. 2013;31(43):4968–74. doi:10.1016/j.vaccine.2013.08.006.
  • Stella M, Giuliani M, Biolchi A, Tomei S, De Paola R, Bai X, Borrow R, Lucidarme J, La Gaetana R, Toneatto D. et al. Does vaccination with 4CMenB convey protection against meningococcal serogroup B strains not predicted to be covered by MATS? A study of the UK clonal complex cc269. Hum Vaccin Immunother. 2020;16(4):945–8. doi:10.1080/21645515.2019.1688039.
  • Abad R, Biolchi A, Moschioni M, Giuliani MM, Pizza M, Vázquez JA. A large portion of meningococcal antigen typing system-negative meningococcal strains from Spain is killed by sera from adolescents and infants immunized with 4CMenB. Clin Vaccine Immunol. 2015;22(4):357–60. doi:10.1128/cvi.00669-14.
  • Viviani V, Biolchi A, Pizza M. Synergistic activity of antibodies in the multicomponent 4CMenB vaccine. Expert Rev Vaccines. 2022;21(5):645–58. doi:10.1080/14760584.2022.2050697.
  • Kleinschmidt A, Vadivelu K, Serino L, Neidig N, de Wergifosse B. Endogenous complement human serum bactericidal assay (enc-hSBA) for vaccine effectiveness assessments against meningococcal serogroup B. NPJ Vaccines. 2021;6(1):29. doi:10.1038/s41541-021-00286-8.
  • Welsch JA, Senders S, Essink B, Klein T, Smolenov I, Pedotti P, Barbi S, Verma B, Toneatto D. Breadth of coverage against a panel of 110 invasive disease isolates, immunogenicity and safety for 2 and 3 doses of an investigational MenABCWY vaccine in US adolescents - Results from a randomized, controlled, observer-blind phase II study. Vaccine. 2018;36(35):5309–17. doi:10.1016/j.vaccine.2018.07.016.
  • Muzzi A, Bodini M, Topaz N, Masignani V, Vadivelu K, Marjuki H, Wang X, Serino L, Medini D. Genetic features of a representative panel of 110 meningococcal B isolates to assess the efficacy of meningococcal B vaccines. mSphere. 2022;7(5):e0038522. doi:10.1128/msphere.00385-22.
  • EU Clinical Trials Register. Clinical trial results: A phase III, randomized, controlled, observer-blind study to demonstrate effectiveness, immunogenicity and safety of GSK’s meningococcal Group B and combined ABCWY vaccines when administered to healthy adolescents and young adults. 2024 [accessed 2024 Mar 15]. https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001666-15/results.
  • ClinicalTrials.gov. Effectiveness of GlaxoSmithKline Biologicals S.A’s meningococcal group B and combined ABCWY vaccines in healthy adolescents and young adults. 2024 [accessed 2024 Mar 15]. https://www.clinicaltrials.gov/ct2/show/NCT04502693.
  • New York State Department Of Health AIDS Institute. Immunizations for adults with HIV. Meningococcal Serogroup B. 2023 [accessed 2024 Mar 15]. https://www.hivguidelines.org/guideline/hiv-immunizations/?mytab=tab_10&mycollection=hiv-care.
  • Mahase E. Routinely offer MenB jabs to prevent gonorrhoea, UK vaccine committee recommends. BMJ. 2023;383:2696. doi:10.1136/bmj.p2696.
  • Pinto Cardoso G, Lagrée-Chastan M, Caseris M, Gaudelus J, Haas H, Leroy JP, Bakhache P, Pujol JF, Werner A, Dommergues MA. et al. Overview of meningococcal epidemiology and national immunization programs in children and adolescents in 8 Western European countries. Front Pediatr. 2022;10:1000657. doi:10.3389/fped.2022.1000657.
  • Herrera-Restrepo O, Clements DE, Conley WJ, Marshall GS. Expert perspectives on the vaccination of individuals who are at increased risk of meningococcal disease due to medical conditions: a podcast. Infect Dis Ther. 2023;12(4):1019–27. doi:10.1007/s40121-023-00778-1.
  • Ballalai I, Dawson R, Horn M, Smith V, Bekkat-Berkani R, Soumahoro L, Vicic N. Understanding barriers to vaccination against invasive meningococcal disease: a survey of the knowledge gap and potential solutions. Expert Rev Vaccines. 2023;22(1):457–67. doi:10.1080/14760584.2023.2211163.
  • McMillan M, Chandrakumar A, Wang HLR, Clarke M, Sullivan TR, Andrews RM, Ramsay M, Marshall HS. Effectiveness of meningococcal vaccines at reducing invasive meningococcal disease and pharyngeal Neisseria meningitidis carriage: a systematic review and meta-analysis. Clin Infect Dis. 2021;73(3):609–19. doi:10.1093/cid/ciaa1733.
  • McMillan M, Koehler AP, Lawrence A, Sullivan TR, Bednarz J, MacLennan JM, Maiden MCJ, Ladhani SN, Ramsay ME, Trotter C. et al. B Part of it school leaver study: A repeat cross-sectional study to assess the impact of increasing coverage with meningococcal B (4CMenB) vaccine on carriage of Neisseria meningitidis. J Infect Dis. 2022;225(4):637–49. doi:10.1093/infdis/jiab444.
  • Marshall HS, Andraweera PH, Ward J, Kaldor J, Andrews R, Macartney K, Richmond P, Krause V, Koehler A, Whiley D. et al. An observational study to assess the effectiveness of 4CMenB against meningococcal disease and carriage and gonorrhea in adolescents in the Northern Territory, Australia - study protocol. Vaccines (Basel). 2022;10(2):309. doi:10.3390/vaccines10020309.
  • Carr J, Plested E, Aley P, Camara S, Davis K, MacLennan JM, Gray S, Faust SN, Borrow R, Christensen H. et al. ‘Be on the TEAM’ study (teenagers against meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents. BMJ Open. 2020;10(10):e037358. doi:10.1136/bmjopen-2020-037358.